Phase II Topical Interferon Alpha-2b trial for AGW: Helix BioPharma achieves last-patient-out

NewsGuard 100/100 Score
Mar 22 2010

Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) announced today that it has achieved last-patient-out in its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW).  Accordingly, all patients enrolled in the study have completed the prescribed study procedures, and Helix will now proceed to closing of the database and analysis of the results.  Based on the trial design and schedule, final reporting is expected in mid to late calendar 2010, as previously announced.

SOURCE Helix BioPharma Corp.

Posted in: Drug Trial News | Disease/Infection News

Tags: , , , , , ,

Comments (0)

Suggested Reading

Study suggests patients with severe long COVID present with variable symptoms, do not cluster in relation to organs affected or immunological states
Circulatory cholesterol levels are inversely linked to mortality of patients with sepsis and critical illness
Pangolins' genetic makeup linked to increased coronavirus susceptibility
Repurposed nasal antibiotic neomycin shows promise in preventing and treating respiratory viral infections
Sesame protein-derived peptides show promise in fighting E. coli and S. aureus
Study shows Omicron variants evade immune system like predecessors, suggesting key evolutionary trait in SARS-CoV-2
Exploring the global health challenge of hepatitis D
New study finds interferon-γ release assays more effective than skin tests in predicting tuberculosis

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Elevated IFN-γ levels linked to long COVID, study finds